Skip to main content
Antibody Therapeutics logoLink to Antibody Therapeutics
. 2022 Jan 19;5(1):84. doi: 10.1093/abt/tbab029

Corrigendum to: Development of bispecific antibodies in China: overview and prospects

Jing Zhang 1, Jizu Yi 2,, Pengfei Zhou 3,
PMCID: PMC8972275  PMID: 35372785

In the originally published version of this manuscript, the following conflict of interest statement was omitted:

“The authors are employees of Wuhan YZY Biopharma Co., Ltd that develops and commercializes antibody therapeutics including bispecific antibodies.”

This has been corrected.

Contributor Information

Jing Zhang, Wuhan YZY Biopharma Co., Ltd, Biolake City C2-1, No. 666 Gaoxin Road, Wuhan, Hubei 430075, China.

Jizu Yi, Wuhan YZY Biopharma Co., Ltd, Biolake City C2-1, No. 666 Gaoxin Road, Wuhan, Hubei 430075, China.

Pengfei Zhou, Wuhan YZY Biopharma Co., Ltd, Biolake City C2-1, No. 666 Gaoxin Road, Wuhan, Hubei 430075, China.


Articles from Antibody Therapeutics are provided here courtesy of Oxford University Press

RESOURCES